Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The gut hormone fragment peptide YY3-36 (PYY) reduces appetite and food intake when infused into subjects of normal weight. In common with the adipocyte hormone leptin, PYY reduces food intake by modulating appetite circuits in the hypothalamus. However, in obesity there is a marked resistance to the action of leptin, which greatly limits its therapeutic effectiveness. We investigated whether obese subjects were also resistant to the anorectic effects of PYY. METHODS: We compared the effects of PYY infusion on appetite and food intake in 12 obese and 12 lean subjects in a double-blind, placebo-controlled, crossover study. The plasma levels of PYY, ghrelin, leptin, and insulin were also determined. RESULTS: Caloric intake during a buffet lunch offered two hours after the infusion of PYY was decreased by 30 percent in the obese subjects (P<0.001) and 31 percent in the lean subjects (P<0.001). PYY infusion also caused a significant decrease in the cumulative 24-hour caloric intake in both obese and lean subjects. PYY infusion reduced plasma levels of the appetite-stimulatory hormone ghrelin. Endogenous fasting and postprandial levels of PYY were significantly lower in obese subjects (the mean [+/-SE] fasting PYY levels were 10.2+/-0.7 pmol per liter in the obese group and 16.9+/-0.8 pmol per liter in the lean group, P<0.001). Furthermore, the fasting PYY levels correlated negatively with the body-mass index (r = -0.84, P<0.001). CONCLUSIONS: We found that obese subjects were not resistant to the anorectic effects of PYY. Endogenous PYY levels were low in the obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“On the other hand, GLP-1 RA can reduce epicardial fat and semaglutide 2.4 mg have shown to improve physical function and symptoms in people with HFpEF [93].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
The Eating Attitudes Test: an index of the symptoms of anorexia nervosa
Garner, D. M., & Garfinkel, P. E. (1979) · Psychological Medicine · doi:10.1017/s0033291700030762 · Cited by 3,543 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationPlasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationObesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479
Cited by
Items 301–400 of 1,003
The Gut Hormones in Appetite Regulation
Suzuki, K., Jayasena, C. N., & Bloom, S. R. (2011) · Journal of Obesity · doi:10.1155/2011/528401 · Cited by 108
“In obese subjects circulating PYY levels are low [33, 40], and PYY levels are reported to be higher in patients with anorexia nervosa when compared with control subjects [41].”
BackgroundSelf-citationRecent advances in clinical practice challenges and opportunities in the management of obesity
Acosta, A., Abu Dayyeh, B. K., Port, J. D., & Camilleri, M. (2014) · Gut · doi:10.1136/gutjnl-2013-306235 · Cited by 91
Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer
Sinclair, P., Brennan, D. J., & le Roux, C. W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0057-y · Cited by 91
GWAS for BMI: a treasure trove of fundamental insights into the genetic basis of obesity
Speakman, J. R., Loos, R. J. F., O’Rahilly, S., Hirschhorn, J. N., & Allison, D. B. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0147-5 · Cited by 108
Adams, S. H., Lei, C., Jodka, C. M., Nikoulina, S. E., Hoyt, J. A., Gedulin, B. R., Mack, C. M., & Kendall, E. S. (2006) · Journal of Nutrition · doi:10.1093/jn/136.1.195 · Cited by 94
Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass
Hage, M. P., & Fuleihan, G. E. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2480-9 · Cited by 104
“RYGB surgery has been associated with an increase in PYY levels [18] and since human data support a negative relationship between PYY and bone; a potential negative impact on bone mass would be anticipated.”
InfluentialInvestigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa
Monteleone, P., Martiadis, V., Rigamonti, A. E., Fabrazzo, M., Giordani, C., Müller, E. E., & Maj, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.004 · Cited by 95
Chapman, I. M. (2007) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2007.06.001 · Cited by 112
Cholecystokinin Regulates Expression of Y2 Receptors in Vagal Afferent Neurons Serving the Stomach
Burdyga, G., de Lartigue, G., Raybould, H. E., Morris, R., Dimaline, R., Varro, A., Thompson, D. G., & Dockray, G. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2493-08.2008 · Cited by 93
“There has been considerable interest in the role of PYY3–36 in regulating food intake (Batterham et al., 2002, 2003).”
BackgroundGastric Sensorimotor Functions and Hormone Profile in Normal Weight, Overweight, and Obese People
Katzka, D. A. (2007) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(08)70028-x · Cited by 91
Neuropeptide Y and peptide YY: important regulators of energy metabolism
Nguyen, A. D., Herzog, H., & Sainsbury, A. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283422f0a · Cited by 89
Ramracheya, R. D., McCulloch, L. J., Clark, A., Wiggins, D., Johannessen, H., Olsen, M. K., Cai, X., Zhao, C.-M., Chen, D., & Rorsman, P. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.091 · Cited by 92
“Circulating PYY levels are drastically reduced in obesity and T2D (Batterham et al., 2003).”
BackgroundEndocrinology of anorexia of ageing
Chapman, I. M. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.02.004 · Cited by 77
Apolipoprotein A-IV, food intake, and obesity
Tso, P., & Liu, M. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.07.032 · Cited by 94
The epidemic of obesity and changes in food intake: the Fluoride Hypothesis
Bray, G. A. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.04.033 · Cited by 111
The Obesity Epidemic: Current and Future Pharmacological Treatments
Hofbauer, K. G., Nicholson, J. R., & Boss, O. (2006) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105256 · Cited by 104
Tan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Albrechtsen, N. J. W., Holst, J. J., & Bloom, S. R. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00469 · Cited by 88
“GLP-1 (7-36) amide, PYY (3-36), andOXMwere purchased from Insight Biotechnology (London, United Kingdom).”
MethodSelf-citationRichards, P., Thornberry, N. A., & Pinto, S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101175 · Cited by 92
Moran, L., Noakes, M., Clifton, P. M., Wittert, G., le Roux, C. W., Ghatei, M. A., Bloom, S. R., & Norman, R. J. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.5.1603 · Cited by 97
“Reductions in total fasting PYY or impaired postprandial PYY (15, 16) or no changes in fasting PYY (17, 18) have been observed in overweight subjects, and it is not known whether PYY is differentially regulated in PCOS.”
BackgroundSelf-citationMetabolic and hormonal changes during the refeeding period of prolonged fasting
Korbonits, M., Blaine, D., Elia, M., & Powell-Tuck, J. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0740 · Cited by 88
Sandberg, J. C., Björck, I., & Nilsson, A. C. (2017) · Nutrition Journal · doi:10.1186/s12937-017-0246-5 · Cited by 99
“It has previously been shown that intravenous infusion with PYY in lean or obese subjects decreased the food intake with 31% respectively 30%, at an ad libitum buffet served after 2 h, compared to infusion with saline [25], indicating an anti-obesogenic potential of PYY.”
BackgroundChanges in Gastrointestinal Hormones and Leptin After Roux‐en‐Y Gastric Bypass Surgery
Beckman, L. M., Beckman, T. R., Sibley, S. D., Thomas, W., Ikramuddin, S., Kellogg, T. A., Ghatei, M. A., Bloom, S. R., le Roux, C. W., & Earthman, C. P. (2011) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607110381403 · Cited by 86
Self-citationGermain, N., Galusca, B., Grouselle, D., Frère, D., Tolle, V., Zizzari, P., Lang, F., Epelbaum, J., & Estour, B. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.10.001 · Cited by 99
“The contrasting situation, between high PYY levels in CTand low levels in obesity, suggests a physiopathologic role in body weight control for this hormone (Batterham et al., 2003; Germain et al., 2007).”
Dietary Resistant Starch Increases Hypothalamic POMC Expression in Rats
Shen, L., Keenan, M. J., Martin, R. J., Tulley, R. T., Raggio, A. M., McCutcheon, K. L., & Zhou, J. (2009) · Obesity · doi:10.1038/oby.2008.483 · Cited by 88
“PYY and GLP-1 are gut-secreted hormones and candidates for antiobesity drugs (11,12).”
BackgroundInfluentialGut–Brain Axis: Regulation of Glucose Metabolism
Heijboer, A. C., Pijl, H., Van den Hoek, A. M., Havekes, L. M., Romijn, J. A., & Corssmit, E. P. M. (2006) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01492.x · Cited by 87
Kovalainen, M., Mönkäre, J., Mäkilä, E. M., Salonen, J., Lehto, V., Herzig, K., & Järvinen, K. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0611-6 · Cited by 87
Morínigo, R., Vidal, J., Lacy, A. M., Delgado, S., Casamitjana, R., & Gomis, R. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31815f6e77 · Cited by 85
“Similarly, Batterham et al failed to find a significant effect of PYY infusion on circulating insulin levels in obese subjects.(7) Our study has several limitations.”
BackgroundFoschi, D., Corsi, F., Lazzaroni, M., Sangaletti, O., Riva, P., Tartara, G. L., Bevilacqua, M. T., Osio, M., Alciati, A., Porro, G. B., et al. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803451 · Cited by 88
Undernutrition and Anorexia in the Older Person
Visvanathan, R., & Chapman, I. M. (2009) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.06.009 · Cited by 100
Neuromedin β: a strong candidate gene linking eating behaviors and susceptibility to obesity
Bouchard, L., Drapeau, V., Provencher, V., Lemieux, S., Chagnon, Y. C., Rice, T., Rao, D. C., Vohl, M., Tremblay, A., Bouchard, C., et al. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.6.1478 · Cited by 88
“Finally, a recent study showed that obese subjects, who are resistant to the effects of leptin, are not resistant to the anorectic effects of the gut hormone PYY (52).”
BackgroundInfluentialBueter, M., Löwenstein, C., Ashrafian, H., Hillebrand, J., Bloom, S. R., Olbers, T., Lutz, T., & le Roux, C. W. (2010) · Obesity Surgery · doi:10.1007/s11695-010-0075-5 · Cited by 84
Self-citationPeptide YY Regulates Bone Remodeling in Mice: A Link between Gut and Skeletal Biology
Wong, I. P. L., Driessler, F., Khor, E. C., Shi, Y.-C., Hörmer, B., Nguyen, A. D., Enriquez, R. F., Eisman, J. A., Sainsbury, A., Herzog, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040038 · Cited by 86
“Conversely, obesity is associated with lower levels of PYY [17] and greater bone mineral density [18].”
BackgroundPharmacological Approaches to Weight Reduction: Therapeutic Targets
Körner, J., & Aronne, L. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0341 · Cited by 90
The role of oxyntomodulin and peptide tyrosine–tyrosine (PYY) in appetite control
Wynne, K., & Bloom, S. R. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0318 · Cited by 96
“Studies have shown that the administration of oxyntomodulin or PYY reduces energy intake in obese human volunteers”
BackgroundSelf-citationBeck, E. J., Tapsell, L. C., Batterham, M. J., Tosh, S. M., & Huang, X. (2009) · Nutrition Research · doi:10.1016/j.nutres.2009.09.012 · Cited by 96
Calderón, G., MCRAE, A. N., Rievaj, J., Davis, J. A., Zandvakili, I., Nord, S. L., Burton, D. B., Roberts, G. P., Reimann, F., Gedulin, B. R., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102759 · Cited by 89
“Moreover, the reduced effect of endogenous BA on the synthesis of FGF19 in obesity is concordant with reports that in obesity there are lower levels of GLP-1 [52,53] and PYY [27,54], which are released after EEC stimulation by BAs and other stimuli [55].”
Koliaki, C. C., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00396-9 · Cited by 92
The hypothalamus, hormones, and hunger: alterations in human obesity and illness
Goldstone, A. P. (2006) · Progress in brain research · doi:10.1016/s0079-6123(06)53003-1 · Cited by 104
Gastrointestinal hormones: the regulation of appetite and the anorexia of ageing
Moss, C., Dhillo, W. S., Frost, G., & Hickson, M. (2012) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2011.01211.x · Cited by 84
Self-citationPeptide YY in adolescent athletes with amenorrhea, eumenorrheic athletes and non-athletic controls
Russell, M., Stark, J., Nayak, S., Miller, K. K., Herzog, D. B., Klibanski, A., & Misra, M. (2009) · Bone · doi:10.1016/j.bone.2009.03.668 · Cited by 83
“Levels of PYY are low in obesity [17] and high in anorexia nervosa [6], indicating altered PYY secretion at the extremes of energy availability.”
BackgroundPedersen, C., Lefevre, S., Peters, V., Patterson, M., Ghatei, M. A., Morgan, L., & Frost, G. S. (2013) · Appetite · doi:10.1016/j.appet.2013.02.017 · Cited by 96
Self-citationEffects of exercise and restrained eating behaviour on appetite control
Martins, C., Robertson, M. D., & Morgan, L. M. (2008) · Proceedings of the Nutrition Society · doi:10.1017/s0029665108005995 · Cited by 83
“PYY plasma levels have been shown to be sensitive to acute and chronic food restriction((130)), to be modulated by gender (with higher levels in females)((131)) and also may possibly be modulated by body weight((131)) (with lower fasting and postprandial levels in obese subjects((132,133))).”
BackgroundLawson, E. A., Eddy, K. T., Donoho, D., Misra, M., Miller, K. K., Meenaghan, E., Lydecker, J., Herzog, D., & Klibanski, A. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0523 · Cited by 83
“Levels of these hormones differ based on body weight and body fat (1-5).”
InfluentialLeveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 83
Espinós, J. C., Turró, R., Moragas, G., Bronstone, A., Buchwald, J. N., Mearin, F., Mata, A., Uchima, H., Turró, J., & Delgado-Aros, S. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1863-8 · Cited by 86
“These findings are in concordance with the known biological functions of PYY [28] and with data from bariatric surgery studies [29-31].”
Rebello, C. J., Burton, J., Heiman, M., & Greenway, F. L. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.08.023 · Cited by 81
“In humans, peripheral administration of the circulating form (PYY3-36) has been shown to increase satiety and reduce energy intake (Batterham et al., 2003).”
BackgroundEffect of ileal fat perfusion on satiety and hormone release in healthy volunteers
Maljaars, J., Symersky, T., Kee, B. C., Haddeman, E., Peters, H. P. F., & Masclee, A. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.166 · Cited by 93
The Gut Hormone Response Following Roux-en-Y Gastric Bypass: Cross-sectional and Prospective Study
Pournaras, D. J., Osborne, A., Hawkins, S. C., Mahon, D., Ghatei, M. A., Bloom, S. R., Welbourn, R., & le Roux, C. W. (2009) · Obesity Surgery · doi:10.1007/s11695-009-9989-1 · Cited by 94
“PYY-like immunoreactivity was measured with a specific and sensitive radioimmunoassay, which measures both the full length (PYY1–36) and the fragment (PYY3–36) [6, 7].”
MethodSelf-citationPeptide YY Regulates Bone Turnover in Rodents
Wortley, K. E., García, K., Okamoto, H., Thabet, K., Anderson, K. D., Shen, V., Herman, J. P., Valenzuela, D. M., Yancopoulos, G. D., Tschöp, M. H., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.024 · Cited by 82
Physical Activity and Hormonal Regulation of Appetite: Sex Differences and Weight Control
Hagobian, T. A., & Braun, B. (2010) · Exercise and Sport Sciences Reviews · doi:10.1097/jes.0b013e3181c5cd98 · Cited by 82
“Peripheral infusion of PYY3Y36, the most common and potent form of PYY, suppresses subsequent food intake in both animals (2) and humans (1).”
BackgroundPeptide YY and appetite control
McGowan, B. M., & Bloom, S. R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.06.007 · Cited by 84
Self-citationNeuropeptide Y Y2 receptor in health and disease
Parker, S. L., & Balasubramaniam, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707445 · Cited by 89
“Inhibition of feeding by an Y2 agonist, PYY(3–36), was first reported by Stephen Bloom and associates (Batterham et al., 2002, 2003).”
BackgroundAppetite‐Regulating Hormone Changes in Patients With Craniopharyngioma
Roth, C. L., Gebhardt, U., & Müller, H. L. (2011) · Obesity · doi:10.1038/oby.2010.80 · Cited by 82
“That said, we know from previous studies that changes of active and total ghrelin are almost parallel (37,38), and PYY3–36, which is the major form regarding effects on food intake, is the predominant circulating form, as PYY1–36 only exists transiently, because it is cleaved to PYY3–36 by the dipeptidyl peptidase IV…”
BackgroundEffects of dipeptidyl peptidase IV on the satiety actions of peptide YY
Unniappan, S., McIntosh, C. H. S., Demuth, H. U., Heiser, U. F., Wolf, R., & Kieffer, T. J. (2006) · Diabetologia · doi:10.1007/s00125-006-0310-8 · Cited by 91
“infusion in lean and obese humans [26], have been shown to inhibit food intake.”
BackgroundOral glucose intake inhibits hypothalamic neuronal activity more effectively than glucose infusion
Smeets, P. A. M., Vidarsdottir, S., de Graaf, C., Stafleu, A., van Osch, M. J. P., Viergever, M. A., Pijl, H., & van der Grond, J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00231.2007 · Cited by 79
“Of particular relevance to the present findings, GLP-1, OXM, and PYY act in the hypothalamus to induce satiety in rodents and humans (1, 2, 9, 10, 15, 39).”
BackgroundGonzalez, R., & Unniappan, S. (2009) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2009.09.008 · Cited by 82
“In addition, similar reductions in food intake have been observed with peripheral administration of PYY(3–36) in monkeys (Moran et al., 2005) and humans (Batterham et al., 2003; Degen et al., 2005; Sloth et al., 2007).”
BackgroundReinehr, T., Roth, C. L., Schernthaner, G.-H., Kopp, H.-P., Kriwanek, S., & Schernthaner, G. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9323-8 · Cited by 87
“Recent findings suggest that low plasma PYY levels may contribute to diet-induced human obesity because fasting PYY concentrations correlated negatively with body-mass index (BMI) [10, 11] and injection of PYY decreased caloric intake in humans [10].”
BackgroundCurrent and Future Drug Targets in Weight Management
Witkamp, R. F. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0341-1 · Cited by 90
“(91) that peripheral administration of PYY3-36 can cause a reduction of food intake in rodents and in obese and normal-weight humans, other studies confirmed the anorectic action of PYY3-36.”
ResultRoth, J. D., Coffey, T., Jodka, C. M., Maier, H., Athanacio, J. R., Mack, C. M., Weyer, C., & Parkes, D. G. (2007) · Endocrinology · doi:10.1210/en.2007-0898 · Cited by 77
“Finally, a 4 3 factorial design was used to formally describe the interaction between amylin and PYY[3–36].”
BackgroundMethodInfluentialScheid, J. L., Williams, N. I., West, S., VanHeest, J. L., & Souza, M. J. D. (2008) · Appetite · doi:10.1016/j.appet.2008.09.016 · Cited by 83
Buhmann, H., le Roux, C. W., & Bueter, M. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.003 · Cited by 102
“Furthermore, obese individuals are not immune to the effects of PYY, as peripheral PYY administration reduces eating to a similar extent as in normal-weight individuals [67].”
BackgroundGut Hormones and Energy Balance, The Future for Obesity Therapy?
Meiliana, A., & Wijaya, A. (2009) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v1i3.99 · Cited by 79
The role of peptide YY in regulating glucose homeostasis
Boey, D., Sainsbury, A., & Herzog, H. (2007) · Peptides · doi:10.1016/j.peptides.2006.07.031 · Cited by 77
“Although these studies suggest that PYY1-36 or PYY3-36 do not have a role in glucose homeostasis, it is important to highlight that PYY levels were measured in obese people that already have high fasting insulin [5], in diabetic subjects that were already insulin resistant [17] or in anorexic subjects who had an eatin…”
BackgroundNeuroendocrine Consequences of Anorexia Nervosa in Adolescents
Misra, M., & Klibanski, A. (2010) · Endocrine Development · doi:10.1159/000262540 · Cited by 79
Intravenous Peptide YY3‐36 and Y2 Receptor Antagonism in the Rat: Effects on Feeding Behaviour
Scott, V., Kimura, N., Stark, J. A., & Luckman, S. M. (2005) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2005.01330.x · Cited by 78
Emerging therapeutic potential for peptide YY for obesity-diabetes
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.005 · Cited by 83
Hao, S., Sternini, C., & Raybould, H. E. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00675.2007 · Cited by 76
“CCK and PYY have been shown to exert a number of biological actions on GI functions, including effects on gastric motility (42), gastric emptying (41, 43, 52), gastric acid secretion (33, 52), pancreatic secretion (30), gallbladder contraction (31), and control of food intake (7, 13, 15).”
BackgroundPresent and Future: Pharmacologic Treatment of Obesity
Glandt, M., & Raz, I. (2011) · Journal of Obesity · doi:10.1155/2011/636181 · Cited by 95
Overview of human obesity and central mechanisms regulating energy homeostasis
Crowley, V. (2008) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2007.007193 · Cited by 87
Postprandial changes in gut regulatory peptides in gastric bypass patients
Holdstock, C., Zethelius, B., Sundbom, M., Karlsson, F. A., & Engström, B. E. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.157 · Cited by 79
Kennett, G. A., & Clifton, P. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.020 · Cited by 82
The effects of short-chain fatty acids on the cardiovascular system
Richards, L. B., Li, M., van Esch, B. C. A. M., Garssen, J., & Folkerts, G. (2016) · PharmaNutrition · doi:10.1016/j.phanu.2016.02.001 · Cited by 81
The Physiology and Potential Clinical Applications of Ghrelin, a Novel Peptide Hormone
Tritos, N. A., & Kokkotou, E. G. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.5.653 · Cited by 81
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
Gut-derived signaling molecules and vagal afferents in the control of glucose and energy homeostasis
Thorens, B., & Larsen, P. J. (2004) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/01.mco.0000134368.91900.84 · Cited by 73
The use of the reinstatement model to study relapse to palatable food seeking during dieting
Calu, D. J., Chen, Y.-W., Kawa, A. B., Nair, S. G., & Shaham, Y. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.030 · Cited by 75
Factors affecting circulating levels of peptide YY in humans: a comprehensive review
Cooper, J. A. (2014) · Nutrition Research Reviews · doi:10.1017/s0954422414000109 · Cited by 87
“Interestingly, one study has even reported that PYY3–36 levels were positively associated with BMI and waist circumference.”
BackgroundResultInfluentialChronic PYY3–36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice
van den Hoek, A. M., Heijboer, A. C., Voshol, P. J., Havekes, L. M., Romijn, J. A., Corssmit, E. P. M., & Pijl, H. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00239.2006 · Cited by 72
“Circulating PYY3–36 levels (in fasting and postprandial condition) are low in obese subjects (2, 39, 44), as are the plasma concentrations of several other gut hormones (10, 20, 27, 35).”
BackgroundObesity: considerations about etiology, metabolism, and the use of experimental models
Junior, L., Junior, L., & Pereira-Lancha (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s25026 · Cited by 93
“51 Plasma levels of PYY are reduced during a fasted state; they increase gradually approximately 15 minutes after meal initiation.”
The role of the vagus nerve in appetite control: Implications for the pathogenesis of obesity
Cork, S. C. (2018) · Journal of Neuroendocrinology · doi:10.1111/jne.12643 · Cited by 77
Corrective responses in human food intake identified from an analysis of 7-d food-intake records
Bray, G. A., Flatt, J.-P., Volaufova, J., DeLany, J. P., & Champagne, C. M. (2008) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26289 · Cited by 72
“Other internal signals related to the termination of food intake include the palatability and mass of the food eaten, the general state of health of the person as reflected in the level of hunger, gastric distension, intestinal distension, gastrointestinal peptides that inhibit (cholecystokinin, polypeptide YY3–36) or…”
BackgroundA Chemical Strategy for Protease Substrate Profiling
Griswold, A. R., Cifani, P., Rao, S. D., Axelrod, A. J., Miele, M. M., Hendrickson, R. C., Kentsis, A., & Bachovchin, D. A. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.03.007 · Cited by 72
“PYY exists in two forms, PYY(1–36) and PYY(3–36) (Batterham et al., 2003), the latter of which is generated by DPP4-mediated removal of its N-terminal NH2-Tyr-Pro dipeptide.”
BackgroundDockray, G. J. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.01.009 · Cited by 83
Ghrelin and appetite control in humans—Potential application in the treatment of obesity
Patterson, M., Bloom, S. R., & Gardiner, J. (2011) · Peptides · doi:10.1016/j.peptides.2011.07.021 · Cited by 87
“[3] Batterham RL, Cohen MA, Ellis SM, le Roux CW, Withers DJ, Frost GS, et al.”
BackgroundSelf-citationCNS-targets in control of energy and glucose homeostasis
Kleinridders, A., Könner, A. C., & Brüning, J. C. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.10.006 · Cited by 84
Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man
Witte, A.-B., Grybäck, P., Holst, J. J., Hilsted, L., Hellström, P. M., Jacobsson, H., & Schmidt, P. T. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.07.013 · Cited by 80
Tomlinson, J., & Stewart, P. M. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0023 · Cited by 82
“and administration of appetite-regulating gastrointestinal peptides”
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
“Exogenous PYY administration significantly reduces food intake in both obese and lean subjects (128, 129).”
BackgroundAppetite- and Weight-Regulating Neuroendocrine Circuitry in Hypothalamic Obesity
Gan, H.-W., Cerbone, M., & Dattani, M. T. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad033 · Cited by 65
“Importantly, although human obesity is associated with PYY deficiency, PYY 3-36 retains its anorexigenic effects in this group, without the development of resistance like that seen with leptin (208, 209).”
Blevins, J. E., Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2007) · Peptides · doi:10.1016/j.peptides.2007.11.003 · Cited by 73
“Obese humans appear to have a blunted plasma PYY response to food intake [4,23], yet PYY(3-36) appears to decrease food intake similarly in lean and obese humans [4].”
BackgroundBrain Circuits Regulating Energy Homeostasis
Horvath, T. L., Diano, S., & Tschöp, M. (2004) · The Neuroscientist · doi:10.1177/1073858403262151 · Cited by 69
Peptide hormones regulating appetite—focus on neuroimaging studies in humans
Schloegl, H., Percik, R., Horstmann, A., Villringer, A., & Stumvoll, M. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1154 · Cited by 70
“remain sensitive to the anorexigenic actions of PYY3–36 administered intravenously [37].”
BackgroundTheilade, S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14270 · Cited by 82
“Exogenous pancreatic polypeptide has been found to decrease food intake in rodents(142) as well as in humans.(115,143) Both fasting and stimulated pancreatic polypeptide levels have been shown to be reduced in humans after RYGB.”
BackgroundChanges in gut hormone profile and glucose homeostasis after laparoscopic sleeve gastrectomy
Papamargaritis, D., le Roux, C. W., Sioka, E., KOUKOULIS, G. N., Tzovaras, G. A., & Zacharoulis, D. (2012) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2012.08.007 · Cited by 72
“Additionally, there was a positive correlation at 12 months post-SG between the change at ODI (delta ODI) and weight loss for all the 3 indices that we have used (delta ODI [0–120], P 1⁄4 .”
BackgroundMethodInfluentialThe Role of Gastrointestinal Hormones in Hepatic Lipid Metabolism
Mells, J., & Anania, F. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358527 · Cited by 70
“Peptide YY (3– 36), a selective NPY Y2 agonist, has been shown in both humans and animal models to reduce food intake, 42,137,138 by suppressing appetite through prohibiting NPY release in the arcuate nucleus.”
BackgroundMechanisms of Disease: the role of gastrointestinal hormones in appetite and obesity
Vincent, R. P., Ashrafian, H., & le Roux, C. W. (2008) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1118 · Cited by 75
“Circulating postprandial PYY levels are lower in obese individuals, suggesting that the hormone has a pathophysiological role in the development of obesity”
BackgroundMorbid Obesity and Sleeve Gastrectomy: How Does It Work?
Papailiou, J., Albanopoulos, K., Toutouzas, K. G., Tsigris, C., Nikiteas, N. I., & Zografos, G. (2010) · Obesity Surgery · doi:10.1007/s11695-010-0148-5 · Cited by 82
“It is a gastrointestinal hormone that is produced by the enteroendocrine L cells and acts on the intestinal epithelium [58] and on hypothalamus [59], while its secretion is correlated to the amount of ingested calories [ 60 ].”
BackgroundThe Top 10 Hot Topics in Aging
Morley, J. E. (2004) · The Journals of Gerontology Series A · doi:10.1093/gerona/59.1.m24 · Cited by 100
“PYY(3-36), another gut hormone, has been shown to inhibit feeding in humans (107) and cause weight loss in mice (108).”
BackgroundOrtiz, A. A., Milardo, L. F., DeCarr, L. B., Buckholz, T. M., Mays, M. R., Claus, T. H., Livingston, J. N., Mahle, C. D., & Lumb, K. J. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.125211 · Cited by 69
“Indeed, intravenous and nasal administration of PYY(3-36) to humans reduces caloric intake (Batterham et al., 2002, 2003; Degen et al., 2005).”
BackgroundElliott, J. A., Docherty, N. G., Eckhardt, H., Doyle, S. L., Guinan, E. M., Ravi, N., Reynolds, J. V., & le Roux, C. W. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001918 · Cited by 76
Metadata
- Authors
- Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-04
- Volume
- 349
- Issue
- 10
- Pages
- 941-948
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170277935
- Cited by
- 1,604
- References
- 27
- Citations by year
- 2026: 31 · 2025: 28 · 2024: 31 · 2023: 29 · 2022: 33 · 2021: 54 · 2020: 40 · 2019: 63 · 2018: 44 · 2017: 61 · 2016: 61 · 2015: 60 · 2014: 78 · 2013: 83 · 2012: 89
- FWCI
- 38.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- PYY3-36, peptide YY, obesity, dietary intake, appetite, ghrelin, leptin resistance, gastrointestinal hormones, hypothalamic regulation of appetite, body mass index, energy intake
- MeSH terms
- Appetite, Double-Blind Method, Eating, Female, Humans, Insulin, Male, Obesity, Peptide Fragments, Cross-Over Studies, Peptide YY, Leptin, Peptide Hormones, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.